You are here:Home-Research Areas-Other Indications-Other Indication

Request The Product List ofOther Indication Other Indication

Cat. No. Product Name CAS No. Information
PC-35445

Danicopan

1903768-17-1

Danicopan (ACH-4471, ACH-0144471) is a highly potent, orally active Factor D inhibitor with Kd of 0.54 nM, inhibits the proteolytic activity of purified Factor D against substrate Factor B in complex with C3b, blocking production of Bb fragment IC50 of 15 nM; significantly reduces complement-mediated hemolysis at concentrations as low as 10 nM in cells from paroxysmal nocturnal hemoglobinuria patients, decreases C3 fragment deposition on paroxysmal nocturnal hemoglobinuria erythrocytes; blocks alternative pathway activity when administered orally to cynomolgus monkeys.

Other Indication

Phase 2 Clinical

PC-35165

ALG1001

1307293-62-4

ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis; ALG1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, connecting the posterior aspect of the vitreous with the internal limiting membrane of the retina. In blocking this pathway, ALG-1001 helps to achieve vitreous breakdown and separation from the retina.

Other Indication

Phase 2 Clinical

PC-43500

Cortexolone 17 alpha-propionate

19608-29-8

Cortexolone 17 alpha-propionate (CB-03-01, Clascoterone) is a topical and peripherally selective androgen antagonist, displays a strong local antiandrogenic activity in hamster's flank organ test, does not exhibit antiandrogenic activity after subcutaneous injection in vivo.

Other Indication

Phase 3 Clinical

PC-63453

A4250

501692-44-0

A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH.

Other Indication

Phase 3 Clinical

PC-62577

Visomitin

934826-68-3

Visomitin (SKQ1 bromide, PDTP) is a mitochondria-targeted antioxidant that decreases transmembrane potential and production of reactive oxygen species (ROS); prevents neuronal loss and synaptic damage in a rat model of spontaneous Alzheimer’s disease, slows development of age-related ocular pathologies in murine, porcine, bovine, and canine model systems.

Other Indication

Approved

PC-62098

LAU159

2055050-87-6

LAU159 is a potent, functionally selective positive modulator of α6β3γ2 GABAA receptor.

Other Indication

Phase 3 Clinical

PC-61855

Elamipretide

736992-21-5

Elamipretide (SS-31, MTP-131, Bendavia) is a novel cell-permeable antioxidant tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that targets inner mitochondrial membrane and prevents oxidative damage of neuronal cells and other cell types; prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function.

Other Indication

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com